Method for detecting related substances in vortioxetine hydrobromide

The detection of nitrosamine impurities (Formula I) in vortioxetine hydrobromide using liquid chromatography-mass spectrometry (LC-MS) with specific chromatographic conditions and mass spectrometry parameters overcomes the shortcomings of existing detection methods, achieving highly sensitive and accurate impurity detection and improving product quality.

CN118980772APending Publication Date: 2024-11-19YAOPHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411224929.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-03
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

There is a lack of effective methods in the current technology to detect nitrosamine genotoxic impurities (Formula I) in vortioxetine hydrobromide, which affects product quality control.

Method used

Liquid chromatography-mass spectrometry (LC-MS) was used with a reversed-phase column packed with octadecylsilane-bonded silica gel. The ratio of mobile phase A (10 mM ammonium formate solution) to mobile phase B (acetonitrile) was 3:7. The impurity content was calculated by external standard method using isocratic elution and electrospray ionization (ESI+).

Benefits of technology

This method achieves highly sensitive, specific, and accurate detection of impurity formula I in vortioxetine hydrobromide, improving the accuracy and safety of product quality control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention provides a liquid chromatography-mass spectrometry method, which is suitable for measuring the content of an impurity shown as a formula I in vothioxetine hydrobromide. According to the method, a reversed-phase chromatographic column taking octadecylsilane chemically bonded silica as a filler is selected, a mixed solution of an ammonium formate solution and acetonitrile is taken as a mobile phase, and isocratic elution is adopted. The method is simple, good in specificity and sensitivity, high in accuracy and beneficial to control over the content of genotoxic impurities in the vortioxetine hydrobromide, and the quality level of the vortioxetine hydrobromide is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of chemical drug analysis, and in particular to a method for detecting related substances in vortioxetine hydrobromide by liquid chromatography-mass spectrometry. Background Art

[0002] Vortioxetine hydrobromide is a 5-hydroxytryptamine (5-HT) reuptake inhibitor and an agonist, partial agonist or antagonist of the 5-HT receptor. It was jointly developed by Lundbeck Pharmaceuticals of Denmark and Takeda Pharmaceuticals of Japan for the treatment of depression.

[0003] .

[0004] Formula I is a nitrosamine genotoxic impurity, and it is necessary to control its content in raw materials and preparations to ensure the quality and safety of the products. However, there is currently no literature or other information disclosing a method for determining the impurity shown in Formula I in vortioxetine hydrobromide. Therefore, in order to control the quality of vortioxetine hydrobromide products, it is necessary to develop a method for detecting the impurity of Formula I in vortioxetine hydrobromide.

[0005] . Summary of the invention

[0006] The present invention provides a method for determining the content of impurities represented by formula I in vortioxetine hydrobromide by liquid chromatography-mass spectrometry, characterized in that it comprises the following chromatographic conditions: Chromatographic column: reverse phase chromatographic column with octadecylsilane bonded silica gel as filler; Mobile phase: Mobile phase A is 10 mM ammonium formate solution, mobile phase B is acetonitrile, mobile phase A: mobile phase B = 3:7; Elution mode: isocratic elution; Ion source: ESI (+).

[0007] Furthermore, the chromatographic column is selected from Waters XBridge C18, Waters Xbridge Shield RP18 and Waters Xselect CSH C18.

[0008] Furthermore, the pH of the mobile phase A is 2.2-3.0.

[0009] Furthermore, the column temperature in the chromatographic conditions is 28-32°C.

[0010] Furthermore, the flow rate in the chromatographic conditions is 0.5 ml / min to 0.6 ml / min.

[0011] Furthermore, the injection volume in the chromatographic conditions is 2-30 μl, preferably 20 μl.

[0012] Furthermore, the chromatographic conditions adopt the following mass spectrometry parameters:

[0013] Furthermore, the detection method further comprises the following steps: (1) Preparation of mobile phase A: Accurately measure 500 ml of ultrapure water, add 315 mg of ammonium formate, mix well, adjust the pH with formic acid, and sonicate. (2) Preparation of reference solution (fresh for immediate use): Take an appropriate amount of reference substance of Formula I, accurately weigh it, and quantitatively dilute it with 50% acetonitrile to prepare a solution containing about 200 ng of Formula I per 1 ml; (3) Preparation of test solution (fresh preparation for immediate use): Accurately weigh about 130 mg of vortioxetine hydrobromide and place it in a 10 ml volumetric flask. Add an appropriate amount of methanol and sonicate to dissolve it. Then add methanol to the volume to make a solution containing about 13 mg of vortioxetine hydrobromide per 1 ml. (4) Detection: Take the above-mentioned reference solution, test solution and 50% acetonitrile (blank solvent) and inject them into the liquid chromatography-mass spectrometer respectively, measure under the above-mentioned chromatographic conditions, and record the chromatogram. Calculate the content of formula I in the test solution according to the reference external standard method.

[0014] The present invention adopts a liquid chromatography-mass spectrometry method, selects a reverse phase chromatographic column with octadecylsilane bonded silica gel as a filler to detect Formula I in vortioxetine hydrobromide, and can use a reference substance external standard method to calculate the content of Formula I in the test solution. The method of the present invention is simple, has good specificity and sensitivity, and is highly accurate, is suitable for the determination of Formula I in vortioxetine hydrobromide, is conducive to the control of the content of genotoxic impurities in vortioxetine hydrobromide, and improves the quality level of vortioxetine hydrobromide. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 is the chromatogram of the reference solution when the chromatographic column is Waters XBridge C18 in Example 1; Figure 2 is the chromatogram of the test solution when the chromatographic column is Waters XBridge C18 in Example 1; Figure 3 is the chromatogram of the spiked test solution when the chromatographic column is Waters XBridge C18 in Example 1; Figure 4 is the chromatogram of the blank solvent when the chromatographic column is Waters XBridge C18 in Example 1; Figure 5is the chromatogram of the reference solution when the chromatographic column is Waters Xbridge Shield RP18 in Example 1; Figure 6 is the chromatogram of the test solution when the chromatographic column is Waters Xbridge Shield RP18 in Example 1; Figure 7 is the chromatogram of the blank solvent when the chromatographic column is Waters Xbridge Shield RP18 in Example 1; Figure 8 is a chromatogram of the reference solution when the chromatographic column in Example 1 is Waters Xselect CSH C18; Fig. 9 is the chromatogram of the test solution when the chromatographic column is Waters Xselect CSH C18 in Example 1; Fig.10 This is the chromatogram of the blank solvent when the chromatographic column in Example 1 is Waters Xselect CSH C18. DETAILED DESCRIPTION

[0016] The content of the present invention is further described in detail below by way of embodiments. However, it should not be understood that the above subject matter of the present invention is limited to the following embodiments. In the absence of conflict, the embodiments and features in the embodiments of the present application can be combined with each other at will.

[0017] Example 1 Liquid chromatography-mass spectrometry (LC / MS / MS) was used to determine the content of the impurity represented by formula I in vortioxetine hydrobromide, and the chromatographic conditions were as follows: Chromatographic column: Waters XBridge C18 (150×4.6mm, 3.5μm), Waters Xbridge ShieldRP18 (150×4.5mm, 3.5μm) or Waters Xselect CSH C18 (150×4.5mm, 3.5μm); Mobile phase: Mobile phase A is 10 mM ammonium formate solution (pH = 2.5), mobile phase B is acetonitrile, mobile phase A: mobile phase B = 3:7; Elution mode: isocratic elution; Flow rate: 0.6ml / min; Column temperature: 30°C; Injection volume: 20 μl; Collection time: 10min; Ion source: ESI (+); Mass spectrometry parameters:

[0018] Experimental steps: (1) Preparation of mobile phase A: Accurately measure 500 ml of ultrapure water, add 315 mg of ammonium formate, mix well, adjust the pH to 2.5 with formic acid, and sonicate for 15 minutes. (2) Preparation of reference solution (fresh for immediate use): Take an appropriate amount of reference substance of Formula I, accurately weigh it, and quantitatively dilute it with 50% acetonitrile to prepare a solution containing about 200 ng of Formula I per 1 ml; (3) Preparation of test solution (fresh preparation for immediate use): Accurately weigh about 130 mg of vortioxetine hydrobromide and place it in a 10 ml volumetric flask. Add an appropriate amount of methanol and sonicate to dissolve it. Then add methanol to the volume to make a solution containing about 13 mg of vortioxetine hydrobromide per 1 ml. (4) Preparation of spiked test solution: Take an appropriate amount of Formula I reference substance, accurately weigh it, and dilute it with 50% acetonitrile to prepare a solution containing about 0.1 mg of Formula I per 1 ml, which is the Formula I stock solution; accurately weigh about 325 mg of vortioxetine hydrobromide, place it in a 25 ml volumetric flask, add an appropriate amount of methanol and ultrasonically dissolve it, accurately add an appropriate amount of Formula I stock solution, and dilute to the mark with methanol to obtain a solution containing about 13 mg of the test substance and about 20 ng of Formula I per 1 ml. (5) Detection: Take the above-mentioned reference solution, test solution, spiked test solution and 50% acetonitrile (blank solvent) and inject them into the liquid chromatography-mass spectrometer respectively, measure under the above-mentioned chromatographic conditions, and record the chromatogram. Calculate the content of formula I in the test solution according to the reference external standard method.

[0019] See the detection spectrum Figure 1 to Figure 10 The results showed that the three chromatographic columns were all capable of detecting the impurity Formula I in vortioxetine hydrobromide.

[0020] Example 2 Liquid chromatography-mass spectrometry (LC / MS / MS) was used to determine the content of Formula I in vortioxetine hydrobromide, and the chromatographic conditions were as follows: Chromatographic column: Waters XBridge C18 (150×4.6mm, 3.5μm); Mobile phase: Mobile phase A is 10mM ammonium formate solution (pH=2.2), 10mM ammonium formate solution (pH=2.5) or 10mM ammonium formate solution (pH=3.0), mobile phase B is acetonitrile, mobile phase A: mobile phase B = 3:7; Other chromatographic conditions were the same as in Example 1.

[0021] Experimental steps: (1) Preparation of mobile phase A: Accurately measure 500 ml of ultrapure water, add 315 mg of ammonium formate, mix well, adjust the pH to 2.2, 2.5 or 3.0 with formic acid, and sonicate for 15 min to obtain three mobile phases A with different pH values. (2) The preparation of the reference solution and the test solution is the same as in Example 1; (3) Detection: Take the above-mentioned reference solution, test solution and 50% acetonitrile (blank solvent) and inject them into the liquid chromatography-mass spectrometer respectively, measure under the above-mentioned chromatographic conditions, and record the chromatogram.

[0022] The test results are shown in Table 1. The three mobile phases A can achieve the determination of Formula I.

[0023] Table 1 .

[0024] Example 3 Liquid chromatography-mass spectrometry (LC / MS / MS) was used to determine the content of Formula I in vortioxetine hydrobromide, and the chromatographic conditions were as follows: Chromatographic column: Waters XBridge C18 (150×4.6mm, 3.5μm); Column temperature: 28°C, 30°C or 32°C; Other chromatographic conditions were the same as in Example 1.

[0025] Experimental steps: (1) The preparation of mobile phase, reference solution and test solution is the same as in Example 1; (3) Detection: Take the above-mentioned reference solution, test solution and 50% acetonitrile (blank solvent) and inject them into the liquid chromatography-mass spectrometer respectively, measure under the above-mentioned chromatographic conditions, and record the chromatogram.

[0026] The test results are shown in Table 2. All three column temperature conditions can achieve the determination of Formula I.

[0027] Table 2 .

[0028] Example 4 Liquid chromatography-mass spectrometry (LC / MS / MS) was used to determine the content of Formula I in vortioxetine hydrobromide, and the chromatographic conditions were as follows: Chromatographic column: Waters XBridge C18 (150×4.6mm, 3.5μm); Flow rate: 0.5ml / min or 0.6ml / min; Other chromatographic conditions were the same as in Example 1.

[0029] Experimental steps: (1) The preparation of mobile phase, reference solution and test solution is the same as in Example 1; (3) Detection: Take the above-mentioned reference solution, test solution and 50% acetonitrile (blank solvent) and inject them into the liquid chromatography-mass spectrometer respectively, measure under the above-mentioned chromatographic conditions, and record the chromatogram.

[0030] The test results are shown in Table 3. All three flow rate conditions can achieve the determination of Formula I.

[0031] Table 3 .

[0032] Example 5 Liquid chromatography-mass spectrometry (LC / MS / MS) was used to determine the content of Formula I in vortioxetine hydrobromide, and the chromatographic conditions were as follows: Chromatographic column: Waters XBridge C18 (150×4.6mm, 3.5μm); Other chromatographic conditions were the same as in Example 1.

[0033] Experimental steps: (1) Preparation of mobile phase A: same as in Example 1; (2) Preparation of Formula I stock solution: Take an appropriate amount of Formula I reference substance, accurately weigh it, and dilute it with 50% acetonitrile to prepare a solution containing about 0.1 mg of Formula I per 1 ml. (3) Preparation of test solution: Prepare three portions in parallel as in Example 1; (4) Preparation of medium-concentration spiked test solution: accurately weigh about 325 mg of vortioxetine hydrobromide, place in a 25 ml volumetric flask, add appropriate amount of methanol and sonicate to dissolve, accurately add appropriate amount of Formula I stock solution, and dilute to the mark with methanol to obtain a solution containing about 13 mg of the test sample and about 200 ng of Formula I per 1 ml. Prepare three replicates in parallel; (5) Preparation of low-concentration spiked test solution: accurately weigh about 325 mg of vortioxetine hydrobromide and place it in a 25 ml volumetric flask. Add an appropriate amount of methanol and ultrasonically dissolve it. Accurately add an appropriate amount of Formula I stock solution and make up to the mark with methanol to obtain a solution containing about 13 mg of the test sample and about 20 ng of Formula I per 1 ml. Prepare 3 copies in parallel. (6) Detection: Take the above-mentioned test solution, the medium concentration level spiked test solution and the low concentration level spiked test solution and inject them into the liquid chromatography-mass spectrometer respectively, measure them under the above-mentioned chromatographic conditions, and record the chromatogram. Calculate the content of formula I in the test solution according to the reference external standard method.

[0034] The test results are shown in Table 4. In the three medium-concentration spiked test solutions, the recovery of Formula I was between 73.1% and 77.5%, the average recovery was 75.8%, and the RSD of the recovery was 3.2%; in the three low-concentration spiked test solutions, the recovery of Formula I was between 74.8% and 81.3%, the average recovery was 77.5%, and the RSD of the recovery was 4.4%. This method has good accuracy and meets the requirements of pharmacopoeia and relevant regulations.

[0035] Table 4 .

Claims

1. A method for determining the content of impurities represented by formula I in vortioxetine hydrobromide by liquid chromatography-mass spectrometry, Features The following chromatographic conditions were included: , Chromatographic column: reverse phase chromatographic column with octadecylsilane bonded silica gel as filler; Mobile phase: Mobile phase A is 10 mM ammonium formate solution, mobile phase B is acetonitrile, mobile phase A: mobile phase B = 3:7; Elution mode: isocratic elution; Ion source: ESI (+).

2. The method according to claim 1, wherein the chromatographic column is selected from Waters XBridge C18, Waters Xbridge Shield RP18 and Waters Xselect CSH C18.

3. The method according to claim 1, wherein the pH of the mobile phase A is 2.2 to 3.

0.

4. The method according to claim 1, wherein the column temperature in the chromatographic conditions is 28-32°C.

5. The method according to claim 1, wherein the flow rate in the chromatographic conditions is 0.5 ml / min to 0.6 ml / min.

6. The method according to claim 1, wherein the injection volume in the chromatographic conditions is 2-30 μl. The method according to claim 6 , wherein the injection volume is 20 μl.

8. The method according to any one of claims 1 to 7, wherein the chromatographic conditions include the following mass spectrometry parameters: 。